Diagnostic Assays for Alzheimer's Disease Biomarkers
Tobias Bittner, Roche Diagnostics

Roche

cobas ®
Life needs answers

Agenda

- **Roche Diagnostics**

- **Roche AD Biomarker Development Program**

- **Analytical Performance Abeta42**

- **Preliminary Analytical Performance tTau**

- **Preliminary Analytical Performance pTau181**

Roche Group

Diagnostic platform
cobas e 601

Fully automated

100 tests available

18 min turnaround time

170 samples per hour

cobas®
Life needs answers

cobas platform
>30,000 placements worldwide

Roche

cobas®
Life needs answers

Roche AD Biomarker Development Program
Goals

CSF Abeta42, tTau, and pTau assays (no multiplexing)

- Enable patient selection for treatment with gantenerumab

- Exploring ways to develop stand-alone diagnostic assays

General Features
Abeta42, tTau, pTau assays

General features	
Assays	Individual Abeta42, tTau, pTau181 (no multiplexing)
Assay format	Sandwich
Sample volume	50 µl per determination
Turn around time	18 min
Degree of automation	fully automated
Platform	cobas e 601
Launchplan	worldwide

Thank you for your attention.

Roche Diagnostics Ltd.
6343 Rotkreuz
Switzerland

COBAS, COBAS E and LIFE NEEDS
ANSWERS are trademarks of Roche

This presentation is our intellectual property. Without our written consent, it shall neither be copied in any manner, nor used for manufacturing, nor communicated to third parties.

cobas®

Life needs answers